Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating African swine fever and application thereof

A technology of African swine fever and a composition, applied in the field of medicine, can solve the problems of reduced enzyme protein activity, interfere with calcium operation, functional disorders, etc., and achieve the effects of improving inflammatory response, shortening the course of disease, and improving the level

Active Publication Date: 2020-12-01
LIANYUNGANG JINKANG HEXIN PHARMA CO LTD
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] 3. Affect energy generation: enzyme protein activity decreases under oxidation and nitration
[0019] 4. Interference with the operation of calcium: the sulfhydryl group of the Na+ / Ca2+ exchange protein is oxidized and dysfunction occurs, resulting in intracellular calcium overload and dysfunction
It has been proved that 5-methyltetrahydrofolate is beneficial to the prevention and protection of cardiovascular diseases by promoting eNOS, but there are few studies reporting that 5-methyltetrahydrofolate has effects on iNOS and macrophage secretion under the condition of innate immune activation. The effect of NO

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating African swine fever and application thereof
  • Pharmaceutical composition for treating African swine fever and application thereof
  • Pharmaceutical composition for treating African swine fever and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0067] NO-induced stabilization of HIF-1α and phosphorylated p53 levels reduced by reactive oxygen species [Thomas DD, RidnourLA, Espey MG, et al. Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem. 2006;281(36) :25984–25993.], and indeed, the addition of antioxidants has a protective effect on nitrosative signaling [Edirisinghe I, Arunachalam G, Wong C, et al. Cigarette-smoke-inducedoxidative / nitrosative stress impairs VEGF- and fluid-shear-stress -mediated signaling in endothelial cells [retracted in: Rahman I. Antioxid RedoxSignal. 2013 Apr 2018(12):1535]. Antioxid Redox Signal. 2010;12(12):1355–1369.], thus NO levels and subsequent downstream signaling Conduction is regulated by reactive oxygen species and is also a factor in modulating redox signaling.

[0068] The expression of NOS requires the simultaneous activation of STAT and NF-κB, and NF-κB acts as the master switch of inflammation, and H 2 o 2 Production-related, NF-κB is regulated by redox. Mo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating African swine fever and application thereof, in particular to a pharmaceutical composition for generating a safe amount of nitric oxide in vivo and application of the pharmaceutical composition. The pharmaceutical composition comprises the following components: an NO toxicity reducing agent, an NO extender and a nitric oxide synthase inducer. The invention provides the pharmaceutical composition which is high in universality and extremely effective in treating pathogenic microorganism infection. The NO toxicity reducing agent is selected from 5-methyltetrahydrofolic acid, NMN and dehydroascorbic acid, the NO extender is selected from arginine, and the nitric oxide synthase inducer is selected from phytohemagglutinin. The present invention provides a new pharmaceutical activity of 5-methyltetrahydrofolate, which has a variety of active effects on the immune system caused by pathogen infection, and can be used for treating or preventing diseases caused by viral infections and other pathogen infections, and in particular, the composition of the present invention is used for preventing or treating African swine fever.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition capable of producing nitric oxide in animals, which can provide safe and sufficient nitric oxide for disease prevention and treatment. Background technique [0002] African swine fever (ASF) is an acute, febrile, highly contact and fatal zoonotic disease caused by African swine fever virus (ASFV). The main hosts of ASFV are various species of domestic pigs, African and Eurasian wild boars, and Ornithodoros ticks, etc. Among them, warthogs and bush pigs can be infected, but do not show clinical symptoms. African wild boars such as warthogs and Ornithodoros ticks are ASFV the host. According to the virulence of ASFV, there are significant differences in the clinical symptoms and infection process of ASF, and the mortality rate of the most acute and acute type infection is 100%. [0003] There is no effective preventive vaccine for African swine fev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/519A61K31/198A61K31/375A61K31/706A61P31/14A61P31/20
CPCA61K45/06A61K31/519A61K31/198A61K31/375A61K31/706A61P31/14A61P31/20A61K2300/00A61P31/12A61P31/04A61K31/365A61P31/16A61K31/4985
Inventor 成永之连增林刘康顾睿
Owner LIANYUNGANG JINKANG HEXIN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com